TITLE

New formulation of clozapine approved

PUB. DATE
April 2004
SOURCE
Drug Topics;4/5/2004, Vol. 148 Issue 7, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the U.S. Food & Drug Administration's approval of clozapine orally disintegrating tablet for the management of schizophrenic patients who are unresponsive to standard drug treatment.
ACCESSION #
12938463

 

Related Articles

  • Commentary on "Clinical studies on the mechanism of action of clozapine; the dopamine—serotonin hypothesis of schizophrenia." Psychopharmacology (1989) 99:S18—S27. Meltzer, Herbert Y. // Psychopharmacology;2002, Vol. 163 Issue 1, p1 

    Comments on a study which examined the mechanism of clozapine. Account of related studies; Overview of the serotonin-dopamine hypothesis; Interpretation of the research findings.

  • Clozapine withdrawal.  // Reactions Weekly;7/30/2011, Issue 1362, p12 

    The article describes the case of a 29-year-old man with schizophrenia who developed catatonia following abrupt stoppage of clozapine.

  • Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. Llorca, Pierre-Michel; Lancon, Christophe; Disdier, Beatrice; Farisse, Jean; Sapin, Christophe; Auquier, Pascal // Journal of Psychiatry & Neuroscience;Jan2002, Vol. 27 Issue 1, p30 

    Evaluates the effectiveness of clozapine in neuroleptic-resistance schizophrenia, in terms of its clinical response and plasma concentrations. Mean endpoint clozapine dosage; Significant correlation found between the daily dosage of clozapine and the plasma levels of clozapine and of its...

  • Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. Procyshyn, Ric M.; Wasan, Kishor M.; Thornton, Allen E.; Barr, Alasdair M.; Chen, Eric Y. H.; Pomarol-Clotet, Edith; Stip, Emmanuel; Williams, Richard; MacEwan, G. William; Birmingham, Laird; Honer, William G. // Journal of Psychiatry & Neuroscience;Sep2007, Vol. 32 Issue 5, p331 

    Objective: Investigators have reported that weight gain attributed to clozapine is associated with its clinical response. However, weight gain is a nonspecific physiological variable that, in itself, does not explain the mechanism underlying this relation. Alternatively, other biological...

  • Atypical and Conventional Antipsychotic Drugs in Treatment- Naive First- Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine. Lieberman, Jeffrey A.; Phillips, Michael; Gu, Hongbin; Stroup, Scott; Peiyan Zhang; Lan Kong; Zhongfu Ji; Koch, Gary; Hamer, Robert M. // Neuropsychopharmacology;May2003, Vol. 28 Issue 5, p995 

    The purported advantages of second-generation or 'atypical' antipsychotics relative to first-generation antipsychotics have not been examined in patients with a first episode of schizophrenia. This flexible-dose study examined efficacy and safety in a randomized, double-blind, 52-week trial,...

  • Clozapine.  // Reactions Weekly;3/28/2009, Issue 1245, p13 

    The article describes the case of a 51-year-old woman who developed pulmonary embolism while being treated with clozapine. The woman developed dyspnoea, chest pain and a pulse oxygen saturation of 90 percent on room air and 95 percent on 3L oxygen after clozapine dosage had been titrated to...

  • Clozapine.  // Reactions Weekly;12/1/2007, Issue 1180, p12 

    The article describes the case of a 40-year-old man who developed sialorrhoea a few weeks after receiving clozapine. The patient, who had been receiving stable doses of clozapine, valproate semisodium and fluphenazine for the past 5 years for the treatment of schizoaffective disorder, was noted...

  • Clozapine/olanzapine.  // Reactions Weekly;8/11/2007, Issue 1164, p12 

    The article describes case reports of hyperglycaemia treated with pioglitazone. Four patient developed hyperglycaemia during treatment with clozapine or olanzapine for schizophrenia or schizoaffective psychosis. All of them were successfully treated with pioglitazone. Three patients in the study...

  • Clozapine/haloperidol/risperidone.  // Reactions Weekly;Aug2015, Vol. 1565 Issue 1, p81 

    The article presents case reports of two patients who developed hair loss associated with hyperprolactinaemia following treatment with risperidone, haloperidol and clozapine.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics